A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.
Solid Tumor
DRUG: Neoantigen mRNA Personalised Cancer SW1115C3
ï¼ŒDose-limiting toxicity incidence (participants who experience DLT), 21 day
Objective response rate(ORR) assessment per RECIST Version 1.1, 1 year
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.